The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Rapid Market Expansion

• Current Market Size: The primary cells market has seen significant growth, increasing from $1.33 billion in 2023 to $1.49 billion in 2024.
• Growth Rate: This represents a compound annual growth rate (CAGR) of 12.2%.
• Historical Drivers:
  • Rising prevalence of cancer
  • Increased investments in regenerative medicine research
  • Growing demand for monoclonal antibodies
  • Advantages of primary human cells over cell lines
  • Increased prevalence of chronic diseases

Future Projections

• Forecast Growth: The market is expected to grow to $2.24 billion by 2028.
• Forecast CAGR: A compound annual growth rate of 10.6% is anticipated.
• Future Drivers:
  • Increasing demand for personalized medicine
  • Growing focus on stem cell research
  • Rising investments in the sector
  • Increasing adoption of cell-based assays
• Major Trends:
  • Demand for human primary cells
  • Advancements in research tools and technologies
  • Adoption of cell-based therapies

View More On The Primary Cells Market Report 2024 – https://www.thebusinessresearchcompany.com/report/primary-cells-global-market-report

Government Funding Boost

• Impact of Funding: Rising government funding for cancer research is expected to drive market growth.
• Funding Allocation:
  • Financial support for research projects
  • Personnel support and equipment
  • Infrastructure, training, education, and technology development
• Notable Example: In May 2022, the American Institute for Cancer Research (AICR) requested $49 billion in 2023, up from $46.4 billion the previous year.

Key Companies in the Market

• Major Players:
  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • BD Biosciences
  • Corning Incorporated
  • Cytiva
  • Lonza Group Ltd
  • Charles River Laboratories Inc.
  • STEMCELL Technologies Inc
  • American Type Culture Collection
  • Cell Signaling Technology
  • ZenBio Inc.
  • StemBioSys Inc

Innovations and Acquisitions

• Enhanced Cell Products:
  • Thermo Fisher Scientific Inc launched Gibco CTS OpTmizer Pro Serum Free Medium in January 2021.
  • Purpose: Designed for the growth and expansion of human T lymphocytes used in allogeneic cell therapies.
  • Benefits: Improves central memory phenotype, supports high-density cultures, and is compatible with automation.
• Recent Acquisitions:
  • AnaBios Corporation acquired Cell Systems in April 2023.
  • Objective: Expand their portfolio of human tissue and cell products to enhance research tools and reagents.

Market Segmentation

• By Type:
  • Hematopoietic cells
  • Dermatophytes
  • Gastrointestinal Cells
  • Hepatocytes
  • Lung Cells
  • Renal Cells
  • Heart Cells
  • Musculoskeletal Cells
  • Other Primary Cells
• By Origin:
  • Human Primary Cells
  • Animal Primary Cells
• By End User:
  • Pharmaceuticals
  • Biotechnology Companies
  • Contract Research Organizations (CRO)
  • Academic and Research Institutes
  • Other End Users

Regional Insights

• Leading Region: North America was the largest market for primary cells in 2023.

The primary cells market is poised for continued expansion, driven by technological advancements, increased funding, and a growing focus on personalized medicine and cell-based therapies.

Request A Sample Of The Global Primary Cells Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=14165&type=smp